Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BX Other drugs affecting bone structure and mineralization
M05BX06 Romosozumab
D10156 Romosozumab (USAN) <JP/US>
USP drug classification [BR:br08302]
Metabolic Bone Disease Agents
Sclerostin Inhibitors
Romosozumab
D10156 Romosozumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D10156 Romosozumab (USAN); Romosozumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
D10156 Romosozumab
Drug classes [BR:br08332]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
D10156 Romosozumab
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Signaling molecules
Wnt signaling
SOST
D10156 Romosozumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10156
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10156
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10156
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10156
